NCT00183261: MRKAd5 therapeutic HIV vaccine after early treatment

Medicine Signal Editorial Desk
Updated 2026-10-10

Registry status when checked 2026-10-10Completed

This phase 2 HIV study tested a therapeutic MRKAd5 gag/pol/nef vaccine versus placebo in people treated early after HIV infection. The NIAID/ACTG protocol was AIN504/A5218. Its registry reports 25 actual participants and completion in October 2010. 1 2

Participants were already receiving suppressive antiretroviral therapy. Vaccination was followed, in eligible participants, by a tightly monitored analytical treatment interruption, with viral-load/CD4 monitoring and restart criteria. Planned outcomes included HIV RNA after interruption and serious/severe toxicities. This was not a preventive vaccine trial in uninfected people. 1 2

No verified efficacy estimate from this exact study was established here. The background papers linked in its record predate the trial and cannot be treated as its results. The protocol provides no justification for independently stopping prescribed antiretroviral treatment. 1 2

Sources

1. ClinicalTrials.gov — ClinicalTrials.gov — NCT00183261. Original study registration: sponsor, design, population, endpoints and dated history.Original study registration · Original record checked against the registry API. Checked 2026-10-10. Registration and current registry fields do not by themselves establish efficacy. Historical details in the article retain their stated date. Supplied note: ClinicalTrials.gov — NCT00183261. Original study registration: sponsor, design, population, endpoints and dated history.

2. ICH GCP — ICH GCP — readable reproduction of the sponsor-submitted ClinicalTrials.gov record. Supports the registration details quoted here; not an independent clinical-results publication.Cited supporting source · Link and description preserved from supplied research. Checked in supplied research dated 2026-10-10. Source description comes from supplied research; underlying page was not independently re-read for this update.